Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity

Archive ouverte

Escudier, Marion | Cautela, Jennifer | Malissen, Nausicaa | Ancedy, Yann | Orabona, Morgane | Pinto, Johan | Monestier, Sandrine | Grob, Jean-Jacques | Scemama, Ugo | Jacquier, Alexis | Lalevee, Nathalie | Barraud, Jeremie | Peyrol, Michael | Laine, Marc | Bonello, Laurent | Paganelli, Franck | Cohen, Ariel | Barlesi, Fabrice | Ederhy, Stephane | Thuny, Franck

Edité par CCSD ; American Heart Association -

International audience. Immune checkpoint inhibitors (ICIs) represent a major advance in the treatment of cancer. Although clinical trials reported a low incidence of immune-related cardiovascular adverse events, the number of published life-threatening cases of cardiotoxicity is increasing. In this descriptive observational analysis, we aimed to describe the clinical manifestations, management, and outcomes of patients who developed ICI-related cardiotoxicity.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion